Liposomal CBD Injection Technology (LPT-CBD) patent was allowed in Japan

Executive Summary

• Innocan Pharma announced that its LPT‑CBD patent has been allowed in Japan, the world’s third‑largest pharmaceutical market (~$102 B).
• The allowance adds to an existing granted patent in India, expanding Innocin’s global IP portfolio for its prolonged‑release liposomal CBD formulation.
• The company highlighted ongoing pre‑IND progress with the U.S. FDA and reiterated its development plan toward regulatory approval of LPT‑CBD as a non‑opioid chronic pain therapy.

Key Details

• Patent Scope: Covers a prolonged‑release liposome‑based formulation that encapsulates synthetic CBD for sustained bloodstream exposure (up to four weeks).
• Geographic Coverage: Allowed in Japan; pending administrative steps before formal grant. Part of a broader international family under examination in multiple jurisdictions.
• Existing IP: Granted patent already issued in India for the same technology.
• Market Significance: Japan valued at ~US$102 B, representing a major opportunity for non‑opioid pain therapeutics.
• Collaboration: Technology developed jointly with Professor Chezy Barenholz and Dr. Ahuva Cern (Hebrew University, Jerusalem).
• Regulatory Progress: Following a successful pre‑IND meeting, the U.S. FDA provided positive feedback to advance LPT‑CBD development.
• Quotes:
• “We are thrilled to receive this patent allowance… strengthening our innovation and global IP position.” – Iris Bincovich, CEO.
• “The allowance of this patent provides strong evidence to the dedication and expertise of our development teams…” – Prof. Chezy Barenholz, Advisory Board Chair.
• Forward‑Looking Statements: Company expects continued patent approvals worldwide and advancement toward FDA approval; subject to typical regulatory and market risks.

Notable Quotes

“This allowance marks our second patent to be granted for LPT‑CBD… we look forward to a series of additional patent approvals worldwide.” – Iris Bincovich, CEO
“The allowance of this patent provides strong evidence to the dedication and expertise of our development teams in driving innovation.” – Prof. Chezy Barenholz, Advisory Board Chair

Materiality Assessment: Material – Positive (significant IP protection in a major market that could materially impact future revenue potential).